01—Abstract
Summary
Summary of the 8-K filed September 3, 2026. Cited figures are marked; the original filing is the authoritative source.
On September 3, 2026, AbbVie (NYSE: ABBV) announced completion of its acquisition of Apogee Therapeutics (NASDAQ: APGE), with Apogee shareholders receiving $135.11a per share in cash, for a total equity value of approximately $10.9 billion.
Apogee's stock ceased trading before market open that day. The deal adds an immunology pipeline led by zumilokibart (APG777), a late-stage, half-life extended anti-IL-13 monoclonal antibody in development for atopic dermatitis, plus APG273, a combination of zumilokibart with APG333 (an anti-TSLP antibody) targeting asthma. For investors, the key financial impact is dilution to near-term earnings.
AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14b in 2026 (partial year) and approximately $0.46 in 2027, with accretion not expected until 2032. The company reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and its third-quarter guidance of $3.84 to $3.88. The 2026 guidance already includes the $0.14 Apogee dilution and $0.58 per share of year-to-date acquired IPR&D and milestone expense through Q2, but excludes any acquired IPR&D and milestone charges beyond Q2 because the company says these cannot be reliably forecast.
The filing is a Regulation FD disclosure, so the press release is furnished rather than filed. It carries forward-looking-statement risks, notably the possibility that acquired IPR&D assets do not replicate early clinical results, integration difficulty, and unknown liabilities. The filing does not disclose the deal's financing structure or the effect on AbbVie's balance sheet, so investors should review the company's upcoming filings for those details.
02—Key points
Key Highlights
- Acquisition of Apogee Therapeutics completed September 3, 2026, at $135.11 per share in cash, a total equity value of about $10.9 billion.
- Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended anti-IL-13 antibody in development for atopic dermatitis; Phase 2 showed roughly two-thirds of patients achieving significant skin clearance at 16 weeks.
- APG273 pairs zumilokibart with APG333, an anti-TSLP antibody, as a potential long-acting asthma combination; Phase 1b interim data in asthma were positive.
- The deal is dilutive to adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion expected to begin in 2032.
- 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and Q3 guidance of $3.84 to $3.88 were reaffirmed; both include the Apogee dilution.
- 2026 guidance includes $0.58 per share of acquired IPR&D and milestone expense incurred through Q2 and excludes any such charges after Q2, which the company says cannot be reliably forecast.
- Risks flagged include IPR&D assets failing in later-stage trials, integration challenges, and unknown or contingent liabilities assumed in the acquisition.
03—Questions
Frequently Asked Questions
How much did AbbVie pay for Apogee Therapeutics?
AbbVie paid $135.11 per Apogee share in cash, for a total equity value of approximately $10.9 billion. Apogee's stock stopped trading on NASDAQ before market open on September 3, 2026.
Will the Apogee acquisition affect AbbVie's earnings?
Yes, in the near term. AbbVie expects the deal to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032. The 2026 guidance of $13.87 to $14.07 already reflects the 2026 impact.
Did AbbVie change its 2026 guidance?
No. AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and its Q3 guidance of $3.84 to $3.88. The guidance excludes acquired IPR&D and milestone charges incurred after Q2 2026, which the company says cannot be reliably forecast.
What is the main value driver in the Apogee pipeline?
Zumilokibart, an IL-13 antibody in late-stage development for atopic dermatitis, is the lead asset. The company cites Phase 2 results in which about two-thirds of patients achieved significant skin clearance at 16 weeks, along with itch improvement and support for quarterly or twice-yearly maintenance dosing. Its success in later-stage trials is not assured.
What are the main risks for investors?
Key risks include acquired IPR&D assets failing to replicate early results in larger or later-stage trials, the company failing to realize expected synergies or integrating Apogee on schedule, unknown or contingent liabilities, and the possibility of further IPR&D and milestone charges that are not in guidance.
04—Continue